Opinion|Videos|January 13, 2026
Key Updates With CAR T-Cell Therapy in Myeloma From ASH 2025
Maximilian Merz, MD, and Carrie Bellerive, BS, RN, BMTCN, discuss other key CAR T-cell therapy updates to emerge from the 2025 ASH Annual Meeting.
Advertisement
Episodes in this series
Maximilian Merz, MD, and Carrie Bellerive, BS, RN, BMTCN, highlight other important CAR T-cell therapy updates in multiple myeloma presented at the 2025 ASH Annual Meeting. They discuss advances in product design, real-world outcomes, and supportive care strategies. Merz and Bellerive place these updates in context of the rapidly evolving cellular therapy landscape.
Advertisement
Related to this article
The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.
Pankit Vachhani, MD, discusses the importance of hematocrit control in the management of polycythemia vera.
Pembrolizumab plus denosumab produced a 31% ORR and 53% 6-month PFS rate in VEGFR-TKI-pretreated advanced clear cell renal cell carcinoma.
A new study suggests genomic newborn screening could identify children at risk for early cancers and enable earlier diagnosis and less toxic treatment.
The CLDN18.2/CD47 bispecific antibody spevatamig has received FDA fast track designation for advanced and metastatic biliary tract carcinoma.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Hamza Hashmi, MD, discusses the evolving role and implementation of CAR T-cell therapy in early relapsed/refractory multiple myeloma.
The HER2-directed ADC produced confirmed responses across both biomarker-defined cohorts of advanced salivary gland carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
The OncFive: Top Oncology Articles for the Week of 8/9
3
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
4
Novel Approaches for Hematocrit Control Are Driving Research in Polycythemia Vera
5